Cipher Pharmaceuticals Inc.
Cipher Pharmaceuticals Inc. Fundamental Analysis
Cipher Pharmaceuticals Inc. (CPHRF) shows strong financial fundamentals with a PE ratio of 16.24, profit margin of 34.69%, and ROE of 16.11%. The company generates $0.1B in annual revenue with strong year-over-year growth of 57.66%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 78.2/100 based on profitability, valuation, growth, and balance sheet metrics. The B grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze CPHRF's fundamental strength across five key dimensions:
Efficiency Score
ExcellentCPHRF demonstrates superior asset utilization.
Valuation Score
ExcellentCPHRF trades at attractive valuation levels.
Growth Score
ModerateCPHRF shows steady but slowing expansion.
Financial Health Score
ExcellentCPHRF maintains a strong and stable balance sheet.
Profitability Score
ExcellentCPHRF achieves industry-leading margins.
Key Financial Metrics
Is CPHRF Expensive or Cheap?
P/E Ratio
CPHRF trades at 16.24 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, CPHRF's PEG of 0.38 indicates potential undervaluation.
Price to Book
The market values Cipher Pharmaceuticals Inc. at 2.47 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 14.17 times EBITDA. This signals the market has high growth expectations.
How Well Does CPHRF Make Money?
Net Profit Margin
For every $100 in sales, Cipher Pharmaceuticals Inc. keeps $34.69 as profit after all expenses.
Operating Margin
Core operations generate 28.54 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $16.11 in profit for every $100 of shareholder equity.
ROA
Cipher Pharmaceuticals Inc. generates $11.77 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Cipher Pharmaceuticals Inc. generates strong operating cash flow of $29.88M, reflecting robust business health.
Free Cash Flow
Cipher Pharmaceuticals Inc. generates strong free cash flow of $29.79M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $1.17 in free cash annually.
FCF Yield
CPHRF converts 10.57% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
16.24
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.38
vs 25 benchmark
P/B Ratio
Price to book value ratio
2.47
vs 25 benchmark
P/S Ratio
Price to sales ratio
5.63
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.12
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.30
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.16
vs 25 benchmark
ROA
Return on assets percentage
0.12
vs 25 benchmark
ROCE
Return on capital employed
0.11
vs 25 benchmark
How CPHRF Stacks Against Its Sector Peers
| Metric | CPHRF Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 16.24 | 29.78 | Better (Cheaper) |
| ROE | 16.11% | 792.00% | Weak |
| Net Margin | 34.69% | -23280.00% (disorted) | Strong |
| Debt/Equity | 0.12 | 0.25 | Strong (Low Leverage) |
| Current Ratio | 1.30 | 4.60 | Neutral |
| ROA | 11.77% | -18077.00% (disorted) | Strong |
CPHRF outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Cipher Pharmaceuticals Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
61.40%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
286.78%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
139.61%
Industry Style: Defensive, Growth, Innovation
High Growth